- Entry quantity
- 500 mg vial
- Three-month option
- $119 first month, then $186/month
- Monthly option
- $173 first month, then $196/month
- Other quantity
- 1,000 mg option listed at different rates
- Included
- Visit, medication and shipping described as included
Select the offer before comparing it
Eden lists multiple NAD+ injection options. The entry offer used in our table is the 500 mg three-month selection, advertised at $119 for the first month and $186 per month afterward. The same listed amount on a monthly selection shows different prices: $173 initially and $196 subsequently. Comparing the brand's lowest number without identifying the selection would obscure the actual decision.
A 1,000 mg option is also displayed, but it is not folded into this entry's starting price. A larger listed amount changes the product specification and must be evaluated with its own quote.
A longer plan is a cash-flow question
The three-month label describes a plan condition. It does not by itself establish whether all charges are collected at enrollment, which months receive a promotion, or how cancellation affects an already purchased period. Request the amount due now and the next scheduled invoice before using the offer in an annual worksheet.
For a hypothetical year with one $119 month followed by eleven $186 months, the medication scenario is $2,165. This is an illustrative calculation, not a verified Eden annual quote. Billing timing, eligibility, plan changes and future pricing can alter the amount actually paid.
The amount in the vial is only one specification
The 500 mg label describes total NAD+ amount. It does not specify the liquid volume on its own, so our listing leaves milliliters unknown. A patient should obtain concentration, volume, container count and the pharmacy's labeled usable period rather than infer those details from the number of milligrams.
This is also why we do not publish a cost-per-injection. The prescribed amount and schedule are clinical decisions, and a comparison should not reverse-engineer them to make a plan look inexpensive. The useful financial unit is the actual quoted supply period under the clinician's plan.
Included services and practical follow-up
Eden describes the doctor's visit, medication and shipping as included in its plans and advertises provider messaging. Confirm that these statements apply to the selected NAD+ order and ask about any additional evaluation the clinician recommends. General catalog benefits should be reconciled with the actual checkout and care documents.
Keep clinical messaging distinct from logistics support. A question about a delayed package requires a different answer from a question about a new symptom. Before paying, identify both routes of contact and the procedure if the medication arrives with a damaged container or an uncertain temperature history.
Where the evidence fits
Eden positions injections around vitality, energy and focus. Our review does not verify those outcomes for this formulation or infer that a higher vial amount gives a stronger benefit. The commercial plan selector is not a clinical trial, and its price tiers should not be read as a ladder of effectiveness.
This product is most fairly compared after a clinician has established whether an NAD+ prescription is appropriate and which specification is intended. At that point, compare the initial commitment, later rate and usable supply with similar injection offers. Keep cancellation terms in view, because a discounted entry month is a small part of a longer decision.
Useful distinctions
- Initial and later prices are separately displayed
- 500 mg and 1,000 mg options are distinguishable
- Included visit and shipping are described
Limitations to weigh
- Lowest offer is tied to a three-month selection
- Exact invoice timing needs confirmation
- Volume is not established by the amount in milligrams
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.